These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12422001)

  • 61. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients.
    Gérard S; le Goff B; Maugars Y; Berthelot JM
    Joint Bone Spine; 2008 Dec; 75(6):680-7. PubMed ID: 18848489
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Infliximab: in ankylosing spondylitis.
    Robinson DM; Keating GM
    Drugs; 2005; 65(9):1283-91; discussion 1292-4. PubMed ID: 15916451
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
    J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab.
    Huang F; Zhu J; Zhang L; Zhang J; Zhang F; Yu D
    Clin Rheumatol; 2007 Jun; 26(6):920-6. PubMed ID: 17021665
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: results of a 12-week, prospective, open-label, pilot (METALL) study].
    Gaydukova IZ; Rebrov AP; Poddubnyi DA
    Ter Arkh; 2015; 87(5):47-52. PubMed ID: 26155618
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis.
    El-Shabrawi Y; Hermann J
    Ophthalmology; 2002 Dec; 109(12):2342-6. PubMed ID: 12466181
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS; McGuigan LE; McGirr EE
    Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs.
    Tenga G; Goëb V; Lequerré T; Bacquet-Deschryver H; Daragon A; Pouplin S; Lanfant-Weybel K; Le Loët X; Dieu B; Vittecoq O
    Joint Bone Spine; 2011 Jan; 78(1):50-5. PubMed ID: 20646950
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.
    Mulleman D; Lauféron F; Wendling D; Ternant D; Ducourau E; Paintaud G; Goupille P
    Arthritis Res Ther; 2011 Jun; 13(3):R82. PubMed ID: 21639907
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis.
    Kobayashi S; Yoshinari T
    Mod Rheumatol; 2017 Jan; 27(1):142-149. PubMed ID: 27299733
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
    Park W; Yoo DH; Miranda P; Brzosko M; Wiland P; Gutierrez-Ureña S; Mikazane H; Lee YA; Smiyan S; Lim MJ; Kadinov V; Abud-Mendoza C; Kim H; Lee SJ; Bae Y; Kim S; Braun J
    Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study.
    Mörck B; Pullerits R; Geijer M; Bremell T; Forsblad-d'Elia H
    Mediators Inflamm; 2013; 2013():289845. PubMed ID: 24089587
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
    Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
    Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.
    Lorenzin M; Ortolan A; Frallonardo P; Oliviero F; Punzi L; Ramonda R
    BMC Musculoskelet Disord; 2015 Jul; 16():166. PubMed ID: 26205000
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low dose of infliximab is inadequate in most patients with spondylarthropathies.
    Sidiropoulos P; Kritikos HD; Siakka P; Mamoulaki M; Kouroumali H; Voudouris K; Boumpas DT
    Clin Exp Rheumatol; 2005; 23(4):513-6. PubMed ID: 16095121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.